Patents Assigned to US Biologic, Inc.
-
Publication number: 20240102027Abstract: The inventive subject matter includes an antimicrobial peptide vectored composition made of a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules. More specifically these novel recombinant antimicrobial peptide effector molecules exhibit preferential antimicrobial activity. In some embodiments, the antimicrobial activity is facilitated via interaction with the lipid bilayer of the parasitic cell form, leading to membrane pore formation and resulting in cell lysis. The utility of the current inventive subject matter has demonstrated a reduced viability of Eimeira acervulina sporozoites was shown in vitro using a sporozoite killing assay.Type: ApplicationFiled: October 4, 2023Publication date: March 28, 2024Applicants: US BIOLOGIC, INC, The United States of America as represented by the Secretary of AgricultureInventors: Jolieke G. Van Oosterwijk, Luciana Meirelles Richer, Douglas Steven Zetechka, JR., Hyun Soon Lillehoj, Woohyun Kim, Cyril Gay, Christopher Anthony Przybyszewski
-
Patent number: 11850280Abstract: The inventive subject matter includes a viral-vectored composition made of a bacterial expression vehicle expressing one or more recombinant viral protein antigens and its method of use. In particular, this invention relates to a vaccine for oral administration. Preferably, the bacterial expression vehicle is Bacillus subtilis.Type: GrantFiled: March 31, 2021Date of Patent: December 26, 2023Assignee: US Biologic, IncInventors: Jolieke Gerdy van Oosterwijk, Andrew Raymond Peters, Douglas Steven Zatechka, Jr., Luciana Meirelles Richer, Christopher Anthony Przybyszewski
-
Patent number: 11814628Abstract: The inventive subject matter includes an antimicrobial peptide vectored composition made of a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules. More specifically these novel recombinant antimicrobial peptide effector molecules exhibit preferential anti-microbial activity. The utility of the current inventive subject matter has demonstrated a reduced viability of Eimeira acervulina sporozoites in vitro using a sporozoite killing assay. More specifically, the antimicrobial peptide vectored composition is a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules, wherein the one or more recombinant antimicrobial peptide effector molecules are engineered from a NK-lysin gene and the one or more recombinant antimicrobial peptide effector molecules are engineered to express functionally active NK-2.Type: GrantFiled: June 14, 2021Date of Patent: November 14, 2023Assignee: US Biologic, IncInventors: Jolieke Gerdy Van Oosterwijk, Luciana Meirelles Richer, Douglas Steven Zatechka, Woohyun Kim, Hyun Soon Lillehoj, Cyril Gray, Christopher Anthony Przybyszewski
-
Patent number: 11771746Abstract: Through the use of a universal anti-tick antigens, multiple tick-borne diseases that occur over a significant area can be targeted for eradication. The novel reservoir targeted anti-tick treatment is designed to reduce tick numbers and thereby blocking transmission of tick-borne diseases.Type: GrantFiled: January 10, 2022Date of Patent: October 3, 2023Assignee: US Biologic, IncInventors: Jolieke Gerdy van Oosterwijk, Douglas Steven Zatechka, Jr., Luciana Meirelles Richer
-
Publication number: 20230272407Abstract: The inventive subject matter includes an antimicrobial peptide vectored composition made of a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules. More specifically these novel recombinant antimicrobial peptide effector molecules exhibit preferential anti¬microbial activity. The utility of the current inventive subject matter has demonstrated a reduced viability of Eimeira acervulina sporozoites in vitro using a sporozoite killing assay. More specifically, the antimicrobial peptide vectored composition is a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules, wherein the one or more recombinant antimicrobial peptide effector molecules are engineered from a NK-lysin gene and the one or more recombinant antimicrobial peptide effector molecules are engineered to express functionally active NK-2.Type: ApplicationFiled: June 14, 2021Publication date: August 31, 2023Applicants: US Biologic, Inc., The United States of America as represented by the Secretary of AgricultureInventors: Jolieke Gerdy van Oosterwijk, Luciana Meirelles Richer, Douglas Steven Zatechka, Woohyun Kim, Hyun Soon Lillehoj, Cyril Gray, Christopher Anthony Przybyszewski
-
Patent number: 11730161Abstract: Provided herein are mechanisms and methods for the automated distribution of active ingredients (whether oral or contact based) to wild and domestic animal populations as well as a method for monitoring animal activity and estimating consumption and/or application of such ingredients within the population through the utilization of the mechanisms themselves. The inventive device pertains to a manner of delivering either an active oral ingredient or active contact ingredient within a bait pellet or like substrate for ingestion or external contact and/or coating of a target population. The device allows for controlled access of such a bait pellet (or like substrate) for such a target population coupled with the ability to retain freshness thereof for multiple timed access events without the need for human involvement. A properly sized, configured, and automated delivery device is thus provided to meet these needs. Delivery components are also encompassed herein.Type: GrantFiled: April 13, 2021Date of Patent: August 22, 2023Assignee: US Biologic Inc.Inventors: Robert Shane Luttrell, Mason Kauffman, Steven Zatechka, Christopher Przybyszewski
-
Publication number: 20230127041Abstract: Through the use of a universal anti-tick antigens, multiple tick-borne diseases that occur over a significant area can be targeted for eradication. The novel reservoir targeted anti-tick treatment is designed to reduce tick numbers and thereby blocking transmission of tick-borne diseases.Type: ApplicationFiled: January 10, 2022Publication date: April 27, 2023Applicant: US BIOLOGIC, INCInventors: Jolieke Gerdy van Oosterwijk, Douglas Steven Zatechka, Luciana Meirelles Richer
-
Patent number: 11576868Abstract: The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.Type: GrantFiled: April 15, 2020Date of Patent: February 14, 2023Assignee: US Biologic, Inc.Inventors: Douglas Steven Zatechka, Mason Kauffman, Chris Przybyszewski
-
Patent number: 11076578Abstract: Provided herein are mechanisms and methods for the automated distribution of active ingredients (whether oral or contact based) to wild and domestic animal populations as well as a method for monitoring animal activity and estimating consumption and/or application of such ingredients within the population through the utilization of the mechanisms themselves. The inventive device pertains to a manner of delivering either an active oral ingredient or active contact ingredient within a bait pellet or like substrate for ingestion or external contact and/or coating of a target population. The device allows for controlled access of such a bait pellet (or like substrate) for such a target population coupled with the ability to retain freshness thereof for multiple timed access events without the need for human involvement. A properly sized, configured, and automated delivery device is thus provided to meet these needs. Delivery components are also encompassed herein.Type: GrantFiled: April 19, 2017Date of Patent: August 3, 2021Assignee: US Biologic, Inc.Inventors: Robert Shane Luttrell, Mason Kauffman, Steven Zatechka, Christopher Przybyszewski
-
Patent number: 10653630Abstract: The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioacitve agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.Type: GrantFiled: December 21, 2016Date of Patent: May 19, 2020Assignee: US Biologic, Inc.Inventors: Douglas Steven Zatechka, Mason Kauffman, Chris Przybyszewski